Pedro Sánchez‐Rovira
- Oncology top 1%
- Surgery top 2%
- Cancer Research top 1%
- Molecular Biology top 10%
- Pulmonary and Respiratory Medicine top 5%
- Co-authors
- César L. Ramírez-TortosaJosé L. QuilesM. Carmen Ramírez-TortosaSergio Granados‐PrincipalT. OliverSimon CleallMalcolm J. MooreLuigi Dogliotti
- Topics
- Cancer Treatment and Pharmacology (60 papers)Breast Cancer Treatment Studies (53 papers)HER2/EGFR in Cancer Research (43 papers)
- Cited by
- Cancer ResearchOncologyBiochemistry
- Partner nations
- SpainUnited StatesItaly
In The Last Decade
Pedro Sánchez‐Rovira
143 papers receiving 4.4k citations
Hit Papers
Peers
Comparison fields: 5 of 123
- Oncology 2.1k
- Surgery 1.6k
- Cancer Research 1.2k
- Molecular Biology 1.0k
- Pulmonary and Respiratory Medicine 790
Countries citing papers authored by Pedro Sánchez‐Rovira
This map shows the geographic impact of Pedro Sánchez‐Rovira's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pedro Sánchez‐Rovira with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pedro Sánchez‐Rovira more than expected).
Fields of papers citing papers by Pedro Sánchez‐Rovira
This network shows the impact of papers produced by Pedro Sánchez‐Rovira. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pedro Sánchez‐Rovira. The network helps show where Pedro Sánchez‐Rovira may publish in the future.
Co-authorship network of co-authors of Pedro Sánchez‐Rovira
This figure shows the co-authorship network connecting the top 25 collaborators of Pedro Sánchez‐Rovira. A scholar is included among the top collaborators of Pedro Sánchez‐Rovira based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pedro Sánchez‐Rovira. Pedro Sánchez‐Rovira is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 5 | |
| 3 | 9 | |
| 4 | 2 | |
| 5 | 19 | |
| 6 | 6 | |
| 7 | 28 | |
| 8 | 18 | |
| 9 | 32 | |
| 10 | 10 | |
| 11 | 23 | |
| 12 | 2 | |
| 13 | 9 | |
| 14 | 79 | |
| 15 | 7 | |
| 16 | 15 | |
| 17 | 12 | |
| 18 | 2 | |
| 19 | 95 | |
| 20 | Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Studybreakdown → | 1678 |
About Pedro Sánchez‐Rovira
Pedro Sánchez‐Rovira is a scholar working on Cancer Research, Oncology and Pulmonary and Respiratory Medicine, having authored 152 papers that have together received 4.5k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (60 papers), Breast Cancer Treatment Studies (53 papers) and HER2/EGFR in Cancer Research (43 papers). The work is most often cited by research in Cancer Research (1.2k citations), Oncology (2.1k citations) and Biochemistry (223 citations). Pedro Sánchez‐Rovira has collaborated with scholars based in Spain, United States and Italy. Frequent co-authors include César L. Ramírez-Tortosa, José L. Quiles, M. Carmen Ramírez-Tortosa, Sergio Granados‐Principal, T. Oliver, Simon Cleall, Malcolm J. Moore, Luigi Dogliotti, Carla Visseren‐Grul and Peter Wersäll. Their work appears in journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.